EUR/USD 1.16161
0.078%
Gold 4246.65
0.615%
Oil 59.515
0.061%
USD/JPY 155.440
-0.344%
GBP/USD 1.32174
-0.276%
GBP/JPY 205.457
-0.337%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
The final reading of the Eurozone Manufacturing PMI for November was 49.6, below the expected 49.7 and the previous reading of 49.7.Germanys final manufacturing PMI for November was 48.2, below the expected 48.4 and the previous reading of 48.4.On December 1st, Jonas Feldhusen, an economist at Commerzbank Hamburg, stated that the French manufacturing sector remained weak in November, despite a rebound in exports. The final November manufacturing PMI fell to 47.8 from 48.8 in October, confirming the disappointing preliminary reading. The downward trend was particularly pronounced in demand-related sub-indices, leading to a further contraction in production at its fastest pace since February. New orders showed little improvement – only overseas orders saw growth – highlighting continued weakness in domestic demand. This weakness was also reflected in purchasing activity and inventory dynamics. Companies are reducing raw material purchases and simultaneously cutting inventories, indicating declining production demand. Employment contracted again after a brief period of growth from May to October, meaning a net decrease in manufacturing employment in November. Price changes added further pressure. PMI price data showed that manufacturers faced intense competition, limiting increases in output prices. Against this backdrop, corporate profit margins are likely to be squeezed.Frances final manufacturing PMI for November was 47.8, in line with expectations and the previous reading.The yield on German 2-year government bonds hit its highest level since March 28, reaching 2.045%, up 1.5 basis points on the day.

U.S. Restricts Use of J&J's COVID Vaccine Due to Risk of Blood Clots

Charlie Brooks

May 06, 2022 09:38

J2.png


The US Food and Drug Administration said on Thursday that it will restrict adult use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccination owing to the danger of a rare blood clotting condition, the latest setback for the injection that has been supplanted by competitors.


The J&J shot, which was cleared for adult use in the United States in February 2021, may be used in situations when permitted or approved COVID-19 vaccinations are unavailable or if an user is averse to receiving the other two doses, the Food and Drug Administration said.


J&J is one of three vaccinations that are now in use in the United States. The remaining two are from Moderna (NASDAQ:MRNA) and Pfizer, respectively (NYSE:PFE).


The vaccine manufacturer said that it has amended the COVID-19 vaccination information sheet for the United States to include a warning regarding the risk of thrombosis associated with thrombocytopenia syndrome (TTS), an uncommon but potentially fatal illness.


In high-income nations, use of the J&J shot has been limited, owing to reports of rare, possibly fatal blood clots, manufacturing difficulties, including an unintentional component mix-up by a contract manufacturer, and doubts about effectiveness.


The manufacturer revised its projection for COVID-19 vaccine sales last month, citing a supply glut.


TTS, which is characterized by blood clots and a low platelet count, has previously been documented in recipients of the J&J vaccination.


The FDA changed the information sheet for the J&J vaccine in January to reflect the risk of immune thrombocytopenia, after months of similar action by the European Union's medicines authority.


The FDA stated Thursday that after conducting a study into reported instances, the risk of TTS justified restricting the use of the single-dose injection.


In December, the US Centers for Disease Control and Prevention suggested that Americans take mRNA doses from Pfizer or Moderna rather than J&J's vaccination owing to the possibility of blood clotting.


According to the CDC, about 18.7 million Americans got a J&J COVID-19 injection, compared to 217.5 million who received the Moderna vaccination and 340.6 million who received the Pfizer shot.

Suggestion